))
Setting Up a Robust CGT Supply Chain (Part 1)
Manage episode 426413743 series 3554424
Content provided by Quick Group of Companies. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Quick Group of Companies or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Cell & Gene Therapies hold incredible potential for improving – if not saving – human lives. These CGT’s have been called “living drugs” and can heal diseased organs and – we hope – fight diseases that currently have no cure.
Because of these incredible possibilities, related research and development is growing exponentially around the globe, with increasing numbers of complex clinical trials – complex because they require complicated and precisely-timed pickup and delivery of specimens and deliveries. A single hiccup anywhere in terms of pickup, drop-off, temperature, contamination – anything – can cause significant challenges.
So what, exactly, does it take to set up a robust Cell & Gene Therapy supply chain? What should manufacturers, labs, pharmaceutical and biotech companies, and logistics providers consider?
Mike Sweeney can explain. Mike is Global Head of Strategy for CGT and Direct to Patient products (CGT and DTP) at QuickSTAT Global Life Science Logistics. He joins me now to discuss why – for CGT Supply Chains – planning in advance is the best medicine.
For more information on clinical trial logistics, visit our website at quickstat.com.
5 episodes
Share
